↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
argenx's **$156M** Forte tender at **27% premium** secures dermatology optionality while removing capital competition in rare skin disorder development.
$1.62 per share
for the Torrey Pines biotechnology company with
$156 million
representing a
27% premium
to the January 13 close of
$1.27
argenx expects to complete the acquisition by late February
argenx SE commenced a tender offer for Forte Biosciences on January 14, offering $1.62 per share for the Torrey Pines biotechnology company with 96.3 million diluted shares outstanding. The all-cash bid values Forte at approximately $156 million, representing a 27% premium to the January 13 close of $1.27. argenx expects to complete the acquisition by late February, subject to minimum tender and HSR clearance.
Forte Biosciences repositioned itself in 2023 after discontinuing FB-401, an IL-12/23 inhibitor for inflammatory bowel disease that failed Phase 2b endpoints in ulcerative colitis. The company returned $46 million to shareholders via special dividend in April 2024 and refocused on FB-102, a topical phosphodiesterase-4 inhibitor targeting congenital ichthyoses, a family of rare genetic skin disorders affecting approximately 16,000 patients in the United States. Forte's cash position stood at $37.2 million as of September 30, 2024, with a quarterly burn rate near $3.8 million. The tender premium compensates for execution risk while giving argenx immediate access to a late-preclinical dermatology asset without competitive auction dynamics.
The acquisition extends argenx's immunology franchise beyond its $9.7 billion annual run-rate drug Vyvgart, an FcRn blocker approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Dermatology represents a natural adjacency: autoimmune blistering diseases like pemphigus vulgaris share pathophysiology with neuromuscular indications, and argenx already has clinical infrastructure in academic dermatology centers. FB-102's topical formulation addresses a different mechanism—PDE-4 inhibition reduces inflammatory cytokines locally—but targets a patient population argenx can reach through existing rare-disease distribution. The deal also removes $156 million in potential future capital competition for specialized dermatology clinical trial sites and key opinion leaders, a resource constraint that matters more than the absolute dollar outlay for a company with $2.1 billion in cash and marketable securities.
Allocators should track three developments. First, the tender minimum: argenx set the bar at a majority of fully diluted shares, meaning retail holders of Forte's thinly traded stock have material influence over closing by early February. Second, Vyvgart's Q1 2025 sales print in late April will indicate whether argenx's platform thesis justifies diversification or whether management is prematurely allocating capital outside the core FcRn franchise. Third, any disclosure on FB-102's development timeline—argenx has not committed to Phase 1 initiation—will clarify whether this is an earnest pipeline build or an opportunistic tuck-in for tax-loss harvesting and dermatology network access.
The deal prices Forte at 4.2x trailing cash after dividend recapitalization, a valuation that reflects asset risk but also scarcity value in dermatology platforms with no debt and clean IP. argenx's last acquisition, a $1.3 billion purchase of Zai Lab's global Vyvgart rights in 2022, was a revenue-generating asset with established proof-of-concept. This one is earlier, smaller, and cheaper per dollar of balance sheet acquired.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor tender participation by mid-February; the premium suggests argenx sees scarcity value in dermatology infrastructure beyond FB-102's current clinical stage.
For the operator
Watch Vyvgart Q1 sales momentum in April to assess whether argenx can justify platform diversification or should concentrate capital on FcRn expansion.
For the house
No position; scarcity value exists in rare-disease dermatology assets, but execution visibility insufficient to warrant pre-tender participation at current spread.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.